A mucin isoform-based biomarker assay to improve follow-up and treatment of inflammatory bowel diseases (IBD)
Source
Antwerp, University of Antwerp, Faculty of Medicine and Health Sciences, 2026,291 p.
The intestinal barrier in irritable bowel syndrome : insights from preclinical animal models
Source
Antwerpen, University of Antwerp, Faculty of Medicine and Health Sciences, 2026,336 p.
Clinical significance of mucin signatures in inflammatory bowel diseases : a systematic review of their expression patterns, polymorphisms, and post-translational modifications
Source
Inflammatory bowel diseases - ISSN 1078-0998-32:2 (2026) p. 375-389
Using protease inhibitors to prevent intraperitoneal adhesions : effects of nafamostat mesylate, UAMC-00050, GM6001, and enoxaparin in the cecal ligation and puncture model and the ischemic button model
Source
Surgery today - ISSN 0941-1291-56:5 (2026) p. 673-689
Clinicopathological and prognostic significance of mucin signatures in lower gastrointestinal cancer : a systematic review and meta-analysis
Source
The British journal of cancer - ISSN 0007-0920-134:3 (2026) p. 367-376